Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) SVP Paula Green sold 282 shares of the company's stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $44.90, for a total transaction of $12,661.80. Following the sale, the senior vice president now owns 133,433 shares in the company, valued at $5,991,141.70. The trade was a 0.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
Paula Green also recently made the following trade(s):
Shares of NASDAQ TWST traded up $0.33 during midday trading on Thursday, reaching $49.23. The stock had a trading volume of 486,846 shares, compared to its average volume of 939,671. The stock has a 50-day moving average of $45.51 and a 200-day moving average of $46.72. The company has a market capitalization of $2.92 billion, a price-to-earnings ratio of -13.68 and a beta of 1.82. Twist Bioscience Co. has a 12-month low of $27.41 and a 12-month high of $60.90.
Several brokerages have commented on TWST. Barclays dropped their target price on shares of Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating for the company in a research report on Tuesday, November 19th. Evercore ISI raised their price objective on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an "outperform" rating in a report on Tuesday, October 1st. Robert W. Baird upped their target price on Twist Bioscience from $46.00 to $48.00 and gave the stock an "outperform" rating in a report on Tuesday, November 19th. TD Cowen reiterated a "buy" rating and issued a $58.00 price target on shares of Twist Bioscience in a research note on Tuesday, November 26th. Finally, Scotiabank upped their price target on Twist Bioscience from $50.00 to $54.00 and gave the stock a "sector outperform" rating in a research note on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $51.90.
Read Our Latest Research Report on TWST
A number of large investors have recently added to or reduced their stakes in TWST. Wilmington Savings Fund Society FSB bought a new position in shares of Twist Bioscience during the 3rd quarter valued at about $34,000. Signaturefd LLC lifted its position in shares of Twist Bioscience by 63.0% in the third quarter. Signaturefd LLC now owns 792 shares of the company's stock worth $36,000 after buying an additional 306 shares in the last quarter. DekaBank Deutsche Girozentrale bought a new position in Twist Bioscience during the second quarter valued at approximately $61,000. Beaird Harris Wealth Management LLC purchased a new position in Twist Bioscience during the 3rd quarter valued at approximately $95,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in Twist Bioscience by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company's stock worth $98,000 after acquiring an additional 381 shares during the last quarter.
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Twist Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Twist Bioscience wasn't on the list.
While Twist Bioscience currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.